

Vietnam Da Nang conference expert information collection form

Faculty Curriculum Vitae (教师简历)

PS: 表格内容需填写英文!

Name* 名字	Yang Hong	
Email* 电子邮箱	yanghonggx@163.com	
Country* 国家	China	
Date of birth 出生日期	1973.11	
EDUCATIONAL BACKGROUND 教育背景		
Current Affiliation* 当前所属机构	The first affiliated hospital of Guangxi medical university	
Specialty* 专业	Medical Ultrasound	
Education* (50 words) 教育背景 (50字)	1991 -1996 M.D. Major: Clinical Medicine of Guangxi Medical University, Nanning, P. R. China	
Post-Graduate Education* (50 words) 研究生教育背景 (50字)	2017.6-2018.5 Visiting Scholar Dept. of Pathology, University of Pittsburgh, Pennsylvania, USA 2004 - 2007 Ph.D Major: Imaging and Nuclear Medicine Sun Yat-sen University, Guangzhou, P.R. China 1999 - 2002 M.Sc Major: Imaging and Nuclear Medicine Guangxi Medical University, Nanning, P.R. China	
Academic Annointments* (100 words) 学术任命或单位任命 (100字)	Chief physician, Ph.D. supervisor, Post-doctor advisor, Director Dept. of Medical Ultrasound, The First Affiliated Hospital, Guangxi Medical University, Nanning, P.R. China	
Professional Affiliations and Scientific Publications* (100 words) 参与的专业协会或出版刊物 (100字)	1. Vice chair, Oncology Intervention Committee of Chinese Research-hospital Society 2. Standing Committee Member, Interventional Ultrasound Committee of Chinese Ultrasound-medical Engineering Society 3. Chair, Ultrasound Branch of Guangxi Medicine Society 4. Vice chair, Ultrasound Branch of Guangxi Physician Association 5. Chair, Interventional Sonographer Committee of Guangxi Physician Association	

Published articles or research done*

已发表的文章或所做的研究

1. Qin H, Wu YQ, Lin P, Gao RZ, Li X, Wang XR, Chen G, He Y, Yang H. Ultrasound Image-Based Radiomics: An Innovative Method to Identify Primary Tumorous Sources of Liver Metastases. *J Ultrasound Med.* 2021 Jun;40(6):1229-1244.
2. Gao R, Qin H, Lin P, Ma C, Li C, Wen R, Huang J, Wan D, Wen D, Liang Y, Huang J, Li X, Wang X, Chen G, He Y, Yang H. Development and Validation of a Radiomic Nomogram for Predicting the Prognosis of Kidney Renal Clear Cell Carcinoma. *Front Oncol.* 2021 Jul 6;11:613668.
3. Zhao Y, Wu L, Qin H, Li Q, Shen C, He Y, Yang H. Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma. *Clin Imaging.* 2021 Nov;79:173-178.
4. Lin P, Gao RZ, Wen R, He Y, Yang H. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features. *Front Immunol.* 2021 Aug 12;12:715460.
5. Qin H, Wu YQ, Lin P, Gao RZ, Li X, Wang XR, Chen G, He Y, Yang H. Ultrasound Image-Based Radiomics: An Innovative Method to Identify Primary Tumorous Sources of Liver Metastases. *J Ultrasound Med.* 2021 Jun;40(6):1229-1244.
6. Wen R, Huang J, Gao RZ, Wan D, Qin H, Peng YT, Liang YQ, Li X, Wang XR, He Y, Yang H. CT Radiomics for the Prediction of Synchronous Distant Metastasis in Clear Cell Renal Cell Carcinoma. *J Comput Assist Tomogr.* 2021 Sep-Oct 01;45(5):696-703.
7. Zhao YJ, Wu LY, Pang JS, Liao W, Chen YJ, He Y, Yang H. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma. *Bioengineered.* 2021 Dec;12(1):3978-3992.
8. Wu L, Zhao Y, Lin P, Qin H, Liu Y, Wan D, Li X, He Y, Yang H. Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ. *BMC Med Imaging.* 2021 May 17;21(1):84.
9. Gao RZ, Wen R, Wen DY, Huang J, Qin H, Li X, Wang XR, He Y, Yang H. Radiomics Analysis Based on Ultrasound Images to Distinguish the Tumor Stage and Pathological Grade of Bladder Cancer. *J Ultrasound Med.* 2021 Dec;40(12):2685-2697.
10. Qin H, Que Q, Lin P, Li X, Wang XR, He Y, Chen JQ, Yang H. Magnetic resonance imaging (MRI) radiomics of papillary thyroid cancer (PTC): a comparison of predictive performance of multiple classifiers modeling to identify cervical lymph node metastases before surgery. *Radiol Med.* 2021 Oct;126(10):1312-1327.
11. Lin P, Lin YQ, Gao RZ, Wen R, Qin H, He Y, Yang H. Radiomic profiling of clear cell renal cell carcinoma reveals subtypes with distinct prognoses and molecular pathways. *Transl Oncol.* 2021 Jul;14(7):101078.
12. Jiang H, Chen L, Zhao YJ, Lin ZY, Yang H. Machine Learning-Based Ultrasonomics for Predicting Subacromial Impingement Syndrome Stages. *J Ultrasound Med.* 2022 Sep;41(9):2279-2285.
13. Lin P, Jiang H, Zhao YJ, Pang JS, Liao W, He Y, Lin ZY, Yang H. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy. *Int Immunopharmacol.* 2021 Aug;97:107826.
14. Pang JS, Wen DY, He RQ, Chen G, Lin P, Li JH, Zhao YJ, Wu LY, Chen JH, He Y, Qin LT, Chen JB, Li Y, Yang H. Incomplete thermal ablation-induced up-regulation of transcription factor nuclear receptor subfamily 2, group F, member 6 (NR2F6) contributes to the rapid progression of residual liver tumor in

- hepatoblastoma. *Bioengineered*. 2021 Dec;12(1):4289-4303.
- 15.Wen R, Lin P, Wu Y, Yin H, Huang W, Guo D, Peng Y, Liu D, He Y, Yang H. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma. *Eur J Radiol*. 2022 Sep;154:110415.
- 16.Tang ZP, Ma Z, He Y, Liu RC, Jin BB, Wen DY, Wen R, Yin HH, Qiu CC, Gao RZ, Ma Y, Yang H. Ultrasound-based radiomics for predicting different pathological subtypes of epithelial ovarian cancer before surgery. *BMC Med Imaging*. 2022 Aug 22;22(1):147.
- 17.Wen R, Lin P, Gao R, Wu Y, Peng J, Peng Y, Wen D, Yin H, Ma Z, Tang Z, He Y, Yang H. Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists. *Abdom Radiol (NY)*. 2022 May;47(5):1798-1805.
- 18.Lin P, Yang H. EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma. *J Hepatol*. 2022 Sep;77(3):879-880.
- 19.Lin P, Wen DY, Pang JS, Liao W, Chen YJ, He Y, Yang H. Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma. *J Med Virol*. 2022 Mar 21.
- 20.Lin P, Wan WJ, Kang T, Qin LF, Meng QX, Wu XX, Qin HY, Lin YQ, He Y, Yang H. Molecular hallmarks of breast multiparametric magnetic resonance imaging during neoadjuvant chemotherapy. *Radiol Med*. 2023 Feb;128(2):171-183. doi: 10.1007/s11547-023-01595-9. Epub 2023 Jan 21. PMID: 36680710; PMCID: PMC9860227.
- 21.Yin HH, Wen R, Lin P, Yang H, Hu M, Yang H. Ultrasound-guided microwave ablation of soft tissue venous malformations. *J Vasc Surg Venous Lymphat Disord*. 2023 May;11(3):605-609.
- 22.Lin P, Lin YQ, Gao RZ, Wan WJ, He Y, Yang H. Integrative radiomics and transcriptomics analyses reveal subtype characterization of non-small cell lung cancer. *Eur Radiol*. 2023 Sep;33(9):6414-6425.
- 23.Chen, Yuji, Pang, Jinshu, Liao, Wei, Wan, Weijun, Kang, Tong, Gan, Xiangyu, Lin, Peng, Wen, Dongyue, He, Yun and Yang, Hong. "Overexpression of TRIM28 predicts an unfavorable prognosis and promotes the proliferation and migration of hepatocellular carcinoma" *Oncologie*, vol. 25, no. 5, 2023, pp. 481-494.
- 24.Wen R, Huang W, Song R, Qin L, Wu Y, Peng Y, Huang X, He Y, Yang H. Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC. *BMC Med Imaging*. 2023 Sep 11;23(1):122.
- 25.Wen R, Huang F, Lin P, Gao R, Pang J, Wu Y, Yin H, Tang Z, Ma Z, He Y, Yang H. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies. *Abdom Radiol (NY)*. 2023 Dec;48(12):3688-3695.
- 26.Qin Q, Gan X, Lin P, Pang J, Gao R, Wen R, Liu D, Tang Q, Liu C, He Y, Yang H, Wu Y. Development and validation of a multi-modal ultrasomics model to predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *BMC Med Imaging*. 2024 Mar 18;24(1):65.
- 27.Wen D, Chen J, Lin P, Pang J, Pang Y, Chen G, He Y, Yang H. Investigation of Circular RNA Expression Profiles in Ultrasound-guided Incomplete Radiofrequency Ablation Transplanted Tumor Models of Human Liver Cancer. *Mol Biotechnol*. 2024 Jan 28.
- 28.Pang JS, Bai XM, Wan WJ, Kang T, Wen R, Li LP, Yin HH, Lu CM, Wen DY, He Y, Yang H. RAD21: A Key Transcriptional Regulator in the Development of Residual Liver Cancer. *J Hepatocell Carcinoma*. 2024 Feb 5;11:285-304.

Signature

*(Please kindly add
your signature in
the below box)*

签名

(请在下面的方框中
添加您的签名)

A handwritten signature in black ink, consisting of stylized, cursive characters. The signature is located in the upper right portion of the page, within a rectangular box.